GlassScriptPhysician profile
Alan L Buchman
NPI 1104885557
$66,897.80
in general payments reported to CMS, 2019-2025
7 companies · $167 in 2025
The $167 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.55 · 2020: $43K · 2021: $14K · 2022: $111 · 2023: $9,920 · 2024: $60.56 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,700 · Food and Beverage: $348 · Travel and Lodging: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,700.00 |
| Food and Beverage | $347.72 |
| Travel and Lodging | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $57,179.08 | 2020-2023 | Gattex |
| Abbvie INC. | $8,948.00 | 2021-2023 | |
| Cepheid | $412.50 | 2020 | |
| Ironwood Pharmaceuticals, INC | $167.34 | 2025 | |
| Baxter Healthcare | $137.33 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.13 | 2019 | |
| Fresenius Kabi USA, LLC | $15.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Buchman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.